MCIM
PGNX

Meadow Creek Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Meadow Creek Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,642
Closed -$98K – 1396
2018
Q3 		$98K Buy
15,642
+1,122
+8% +$8.62K ﹤0.01% 1229
2018
Q2 		$117K Hold
14,520
– – ﹤0.01% 1158
2018
Q1 		$108K Buy
14,520
+3,410
+31% +$22.7K ﹤0.01% 1185
2017
Q4 		$66K Buy
11,110
+2,816
+34% +$17.1K ﹤0.01% 1248
2017
Q3 		$61K Buy
8,294
+2,002
+32% +$12.7K ﹤0.01% 1236
2017
Q2 		$43K Buy
6,292
+3,366
+115% +$24.8K ﹤0.01% 1257
2017
Q1 		$28K Buy
+2,926
New +$29.2K ﹤0.01% 1258

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Meadow Creek Investment Management's PGNX Position: Q4 2018 in Review

Meadow Creek Investment Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 15,642 shares — an estimated $98K sold.

Meadow Creek Investment Management first reported a position in PGNX in Q1 2017 and held it in 7 quarters. The position peaked at $117K in Q2 2018. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

  • Meadow Creek Investment Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Meadow Creek Investment Management sold 15,642 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $98K.
  • Meadow Creek Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 7 quarters.
  • Meadow Creek Investment Management's Progenics Pharmaceuticals Inc position peaked at $117K in Q2 2018.
  • 150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Meadow Creek Investment Management's 13F filing for Q4 2018, filed 13 Feb 2019.